Legend Biotech Announces New Cell Therapy R&D Facility

Legend Biotech has plans to open a new R&D facility in Philadelphia with plans to advance its portfolio of next-generation cell therapies. The company is studying its experimental cell therapies, which are in early-stage development, to treat different types of cancers.

If all goes according to schedule, the new 31,000 sq ft facility will be completed in the third quarter of 2025 and will open up 55 new full time positions in the area.

The company’s R&D efforts focus on cell therapies to help strengthen patient’s immune systems. With a stronger immune system, the body can better fight against disease on its own. The company is exploring various technologies to treat both blood and solid cancers – from autologous chimeric antigen receptor T-cell therapy (CAR-T) to allogeneic CAR-T, natural killer (NK) cells and gamma-delta (γδ) T cells. 

The life science firm has multiple BCMA-directed autologous therapy candidates in Phase 1, 2, and 3 stages. Their autologous and allogeneic therapies are in preclinical and Phase 1.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.